LL-37 (5 mg Vial) Dosage Protocol

Overview

LL-37, also known as human cathelicidin, is a multifunctional host-defense peptide with documented antimicrobial, immunomodulatory, and pro-healing properties. Clinical exploration has focused primarily on topical and intralesional applications, though a phase I melanoma study evaluated intratumoral injections with documented immune activation signals.

What Is LL-37?

LL-37 is a naturally occurring peptide that links innate immunity and tissue repair. It demonstrates:
– Direct antimicrobial effects through membrane disruption
– Immunomodulation via plasmacytoid dendritic cell and dendritic cell signaling
– Pro-angiogenic activity relevant to wound healing

Biological Mechanisms

The peptide exhibits antimicrobial, anti-biofilm, immunomodulatory, and angiogenic activities across various biological models. LL-37–nucleic acid complexes can be immunostimulatory; prolonged or high local exposure has been associated with inflammatory skin responses in experimental settings.

Standard Dosing Protocol

Reconstitution

– Diluent: 3.0 mL bacteriostatic water per 5 mg vial
– Final Concentration: ~1.67 mg/mL
– Conversion: 1 unit on U-100 insulin syringe ≈ 16.7 mcg

Dosage Schedule (Gradual Titration)

Administration

– Route: Subcutaneous injection
– Frequency: Once daily
– Cycle Length: 8–12 weeks (optional extension to 16 weeks)
– Timing: Consistent daily administration; rotate injection sites

Supplies Required

For an 8–16 week protocol:

Peptide Vials:
– 8 weeks: ~2 vials
– 12 weeks: ~4 vials
– 16 weeks: ~5 vials

Insulin Syringes (U-100):
– 8 weeks: ~56 syringes
– 12 weeks: ~84 syringes
– 16 weeks: ~112 syringes

Bacteriostatic Water (10 mL bottles):
– 8 weeks (2 vials): 1 bottle
– 12 weeks (4 vials): 2 bottles
– 16 weeks (5 vials): 2 bottles

Alcohol Swabs:
– 8 weeks: 2 × 100-count boxes
– 12 weeks: 2 × 100-count boxes
– 16 weeks: 3 × 100-count boxes

Reconstitution Instructions

1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly down vial wall; avoid foaming
3. Gently swirl/roll until dissolved (do not shake)
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
5. Avoid repeated freeze–thaw cycles

Storage Guidelines

Lyophilized Form:
– Store at −20 °C (−4 °F) in dry, dark conditions

Reconstituted Solution:
– Refrigerate at 2–8 °C (35.6–46.4 °F)
– Protect from light
– Avoid repeated freeze–thaw cycles
– Allow vials to reach room temperature before opening to minimize condensation

Injection Technique

– Clean vial stopper and injection site with alcohol; allow to dry
– Pinch skinfold; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate
– Inject slowly and steadily
– Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy
– Use new sterile syringe for each administration
– Dispose in proper sharps container

Potential Benefits

Research indicates:
– Antimicrobial and anti-biofilm activity
– Immunomodulatory effects
– Angiogenic and tissue-repair properties
– Improved healing rates with topical formulations in venous and diabetic ulcers (per clinical wound literature)

Potential Risks & Considerations

– Local injection-site reactions
– Context-dependent pro-angiogenic or pro-tumor signals in certain models
– Long-term/high exposure linked to inflammatory skin changes in experimental studies
– LL-37 biology is context-dependent; cautious interpretation recommended

Important Notes

– This protocol is educational only and does not constitute medical advice
– Per-injection volumes of ≤0.15 mL remain well below typical subcutaneous comfort limits
– No standardized subcutaneous systemic regimen has been established in published human studies
– For improved readability with small volumes, consider 30- or 50-unit insulin syringes
– Rotate sites to limit local irritation
– Inject slowly; wait a few seconds before needle withdrawal to ensure full dose delivery

—

Disclaimer: This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All peptide use should be discussed with qualified healthcare professionals. For research use only.